Ablynx and Merck Serono Further Strengthen Their Collaboration on Co-Discovery and Co-Development of Nanobodies

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

GHENT, Belgium, Sept. 26, 2013 (GLOBE NEWSWIRE) -- Ablynx (Euronext Brussels:ABLX) and Merck Serono, the biopharmaceutical division of Merck KGaA, Darmstadt, Germany,today announced that they have further expanded their relationship through a multi-year research alliance that could lead to at least four co-discovery and co-development collaborations.

Help employers find you! Check out all the jobs and post your resume.

Back to news